Core Viewpoint - Meili Tianyuan Medical Health expects significant financial performance growth for the fiscal year ending December 31, 2025, with projected revenues of at least 3 billion yuan, representing a year-on-year increase of no less than 16% compared to 2024 [1] Financial Performance Summary - Projected revenue for 2025 is expected to be no less than 3 billion yuan, an increase of at least 16% from 2024 [1] - Adjusted net profit is anticipated to be at least 380 million yuan, reflecting a year-on-year growth of no less than 40% compared to 2024 [1] - Net profit is projected to be at least 340 million yuan, which is an increase of no less than 34% from 2024 [1] Growth Drivers Summary - The primary reasons for the performance improvement include accelerated external expansion and strong organic growth [1] - The acquisition of Narier, the second-ranked brand in China's beauty industry, has enhanced market share and contributed to revenue and profit growth [1] - Increased brand momentum and a growing customer base have driven organic revenue growth, while a higher proportion of high-margin medical business revenue has further boosted profit margins [1]
美丽田园医疗健康：预计2025年收入不少于30亿元，同比增长不少于16%